Skip to main content

Table 3 Features for (colo)rectal cancer selected by MPT1 and known to be involved in this type of cancer

From: A kernel-based integration of genome-wide data for clinical decision support

Outcome* Gene/protein Hits Region Function Up/down Reference
W Cox-2 36 1q25.2-q25.3 Progression Up [50]
W IL-1B 36 2q14 Inflammatory response Up [50]
W Ferritin 36 11q13; 19q13.3-q13.4 Iron storage Down [63]
W EGF 36 4q25 Cell growth/proliferation/differentiation Up [64]
W MMP-2 36 16q13-q21 Invasion/metastasis Up [65]
W TGFα 36 2p13 Angiogenesis/cell proliferation Down [51]
W SELE 25 1q22-q25 Progression/metastasis Up [66]
W GM-CSF 24 5q31.1 Maintenance of granulocytes/macrophages Up [67]
W MMP-1 15 11q22.3 Tumor invasion/metastasis/poor prognosis Up [68]
N Reg4 36 1p13.1-p12 Early carcinogenesis Down [69]
N MUC2 36 11p15.5 Deregulated by TNFα Down [70]
N CA1 36 8q13-q22.1 Carbonate dehydratase activity Down [71]
N CA2 36 8q22 Carbonate dehydratase activity Down [71]
N CLDN8 36 21q22.11 Tumorigenesis Down [72]
N CEA 36 19q13.1-q13.2 Cell adhesion; tumor marker for recurrence Down [53]
N IL-1ra 36 2q14.2 Carcinogenesis Up [73]
N CA19-9 36   Tumor marker for recurrence Down [53]
N Ferritin 36 11q13; 19q13.3-q13.4 Iron storage Down [63]
N IL-1beta 36 2q14 Inflammatory response Down [50]
N beta2-microglobulin 36 15q21-q22.2 Metastasis Up [74]
N RARRES1 31 3q25.32-q25.33 Cell proliferation Down [75]
N IL-8 28 4q13-q21 Progression/metastasis Down [52]
N TNFRII 24 1p36.3-p36.2 Apoptosis Up [76]
C ICAM-1 36 19p13.3-p13.2 Metastasis Down [77]
C CEA 36 19q13.1-q13.2 Cell adhesion; tumor marker for recurrence Down [53]
C MMP-2 36 16q13-q21 Invasion/metastasis Up [65]
C Adiponectin 36 3q27 Metabolic/hormonal processes Down [78]
C Thrombospondin-1 36 15q15 Angiogenesis/tumor growth Up [79]
C EGFR 36 7p12 Cell growth/proliferation/differentiation Up [49]
C Tissue factor 35 1p22-p21 Angiogenesis/metastasis Up [80]
C CYP1B1 35 2p21 Drug metabolism Down [81]
C EGF 32 4q25 Cell growth/proliferation/differentiation Up [64]
  1. *W, WHEELER; N, pN-STAGE; C, CRM. Number of occurrences of the gene/protein in the 36 LOO iterations. Up/down-regulation in the good responders with respect to moderate or poor responders; no lymph nodes with respect to at least one regional lymph node; negative CRM with respect to positive CRM. CRC, (colo)rectal cancer.